Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Against the trial’s posted results

• Same as the trial’s posted resultThis paper difference −12.7 (−14.2 to −11.3)Posted, primary outcome difference −12.7 (−14.2 to −11.3), p <0.0001Percentage Change in Body Weight
• Same as the trial’s posted resultThis paper OR 12.6 (8.50–18.7)Posted, primary outcome OR 12.6 (8.50–18.7), p <0.0001Number of Participants Who Achieved Weight Loss Greater Than or Equal (≥) 5% (Yes/No)